



US010278923B2

(12) **United States Patent**
Nielsen et al.

(10) **Patent No.:** **US 10,278,923 B2**
(45) **Date of Patent:** **May 7, 2019**

(54) **ORAL DOSING OF GLP-1 COMPOUNDS**

(71) Applicant: **Novo Nordisk A/S**, Bagsvaerd (DK)

(72) Inventors: **Flemming S. Nielsen**, Roskilde (DK);
Per Sauerberg, Farum (DK)

(73) Assignee: **Novo Nordisk A/S**, Bagsvaerd (DK)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **15/651,043**

(22) Filed: **Jul. 17, 2017**

(65) **Prior Publication Data**

US 2017/0312225 A1 Nov. 2, 2017

Related U.S. Application Data

(63) Continuation of application No. 14/785,493, filed as application No. PCT/EP2014/058974 on May 2, 2014, now abandoned.

(30) **Foreign Application Priority Data**

May 2, 2013 (EP) 13166205

(51) **Int. Cl.**

A61K 38/26 (2006.01)
A61K 38/00 (2006.01)
A61K 38/22 (2006.01)
A61K 38/12 (2006.01)
A61K 9/20 (2006.01)
A61K 9/00 (2006.01)
A61P 3/04 (2006.01)
A61P 3/10 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 9/2013** (2013.01); **A61K 9/0053** (2013.01); **A61K 38/26** (2013.01); **A61P 3/04** (2018.01); **A61P 3/10** (2018.01); **A61K 9/2054** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

9,278,123 B2	3/2016	Sauerberg et al.
2009/0088369 A1	4/2009	Steiness
2013/0053311 A1	2/2013	Kalthoff et al.
2016/0151462 A1	6/2016	Sauerberg et al.

FOREIGN PATENT DOCUMENTS

EP	2565202 A1	3/2013
WO	0066629 A1	11/2000
WO	0248192 A2	6/2002
WO	2005014049 A2	2/2005
WO	2006097537 A2	9/2006
WO	2007024700 A2	3/2007
WO	2007067964 A2	6/2007
WO	2008033888 A2	3/2008
WO	2010020978 A1	2/2010
WO	2012140117 A1	10/2012
WO	2013009545 A1	1/2013

OTHER PUBLICATIONS

Beglinger et al. 2010. Am. J. Clin Nutr. 92:810-7 (Year: 2010).*
Fonseca et al. 2012. Diabetes Care. 35:1225-1231 (Year: 2012).*
Steinert et al., 2010, Am J Clin Nutr, vol. 92, pp. 810-817.
Nauck et al., 2012, Abstracts of the 48th European Association for the Study of Diabetes Annual Meeting of the EASD, Oct. 1-5, 2012, Berlin, Germany, Diabetologia, 2012, vol. 55, Suppl, S7.

* cited by examiner

Primary Examiner — Shulamith H Shafer

(74) *Attorney, Agent, or Firm* — Nonna G. Akopyan

(57) **ABSTRACT**

The present invention relates to improved uses of GLP-1 peptides in oral therapy.

23 Claims, No Drawings